Celularity Inc. Announces Departure of Acting CFO, Appoints Successor
CELU sits 19% above its 52-week low of $1.01 on light trading volume (0.1× avg).
Summary
Celularity Inc. announced the departure of its SVP, Finance and Acting CFO, Joseph DosSantos, and the immediate appointment of John Sprague as the new Acting CFO.
Key Events · Executive and Board Changes · CELU
-
Acting CFO Departs
Joseph DosSantos, SVP, Finance and Acting Chief Financial Officer, left Celularity Inc. for personal reasons on February 27, 2026.
-
New Acting CFO Appointed
John Sprague was immediately appointed as the new Acting Chief Financial Officer of the company on February 27, 2026.
Analysis · CELU · Life Sciences
This 8-K reports a change in a key financial leadership position for Celularity Inc. The departure of an acting CFO, even for personal reasons, can raise questions about stability, particularly for a small-cap company like Celularity. However, the immediate appointment of John Sprague as Acting CFO provides continuity in financial oversight, mitigating potential concerns about a leadership vacuum. Investors will likely monitor future disclosures for a permanent CFO appointment and any impact on financial reporting or strategy.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.6M. The 52-week trading range was $1.01 to $4.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.